| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
21,088 |
18,910 |
$614K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,180 |
4,687 |
$292K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
14,905 |
6,344 |
$211K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,380 |
3,108 |
$156K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,526 |
3,498 |
$116K |
| 80305 |
|
10,788 |
4,106 |
$96K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,238 |
5,846 |
$73K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
777 |
696 |
$64K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,217 |
1,031 |
$41K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,136 |
1,923 |
$37K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,113 |
1,052 |
$34K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
277 |
253 |
$22K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,525 |
1,425 |
$21K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
96 |
76 |
$20K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
941 |
780 |
$19K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
239 |
205 |
$7K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
76 |
71 |
$6K |
| 99201 |
|
325 |
266 |
$5K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
123 |
96 |
$4K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,029 |
936 |
$920.23 |
| 87807 |
|
73 |
64 |
$766.64 |
| 81003 |
|
853 |
774 |
$170.99 |
| J1741 |
Injection, ibuprofen, 100 mg |
57 |
54 |
$58.50 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
18 |
18 |
$41.00 |
| J3490 |
Unclassified drugs |
18 |
16 |
$0.81 |